Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium Clinical research trials and TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium. TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium clinical trial. Test subjects typically obtain the finest healthcare available for their TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium



TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium

For Condition: Bladder Neoplasms,Carcinoma, Transitional Cell,Ureteral Neoplasms,Urethral Neoplasms
Status: Recruiting
Sponsor(s): Sonus Pharmaceuticals ,
Synopsis: Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Histologic diagnosis of transitional cell carcinoma (TCC) of the urothelium including bladder, renal pelvis, ureter, or urethra - Stage IV disease - One and only one prior systemic cytotoxic chemotherapy regimen administered as adjuvant or neoadjuvant chemotherapy or to treat locally advanced or metastatic disease - Adequate hematologic function (ANC >/= 1500 cells/mm3 & platelet count >/= 100,000/mm3) - Serum creatinine Total Enrollment: 44

Location and Contact Information:

Swedish Cancer Institute *Recruiting*
Seattle,  Washington,  98014
United States
Recruiting Toni  Oien 206-386-2831

University of Pennsylvania *Recruiting*
Philadelphia,  Pennsylvania,  19104
United States
Recruiting Lisa  Bearn 215-614-1811


Additional Information:
Study ID Numbers:
  SON-8184-1073; 
Study Start Date: November 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00077688

Other Urethral Neoplasms Studies:
1. A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

2. Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies.

3. TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium

Related Studies:

Other Urethral Neoplasms Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma (TCC) of the Urothelium

Modify your Search

  Other Urethral Neoplasms Clinical Trials
  Other Washington Clinical Trials
  Other Seattle Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103